Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index; none of the 56 sources its claims cite is checked for support yet.

Efficacy and Safety of Axiostat® Hemostatic Dressing in Aiding Manual Compression Closure of the Femoral Arterial Access Site in Patients Undergoing Endovascular Treatments: A Preliminary Clinical Experience in Two Centers

Open access

Abstract

Background: Hemostasis of the femoral arterial access site by manual compression or a vascular closure device is critical to the safe completion of any endovascular procedure. Previous investigations evaluated the hemostatic efficacy at the radial access site of some chitosan-based hemostatic pads. This study aims to assess the efficacy and safety of a new chitosan-based hemostatic dressing, namely Axiostat®, in aiding manual compression closure of the femoral arterial access site in patients undergoing endovascular treatments. Furthermore, the outcomes were compared with evidence on manual compression alone and vascular closure devices. Methods: This investigation is a two-center retrospective analysis of 120 consecutive patients who had undergone, from July 2022 to February 2023, manual compression closure of the femoral arterial access site aided by the Axiostat® hemostatic dressing. Endovascular procedures performed with introducer sheaths ranging from 4 Fr to 8 Fr were evaluated. Results: Primary technical success was achieved in 110 (91.7%) patients, with adequate hemostasis obtained in all cases of prolonged manual compression requirements. The mean time-to-hemostasis and time-to-ambulation were 8.9 (±3.9) and 462 (±199) minutes, respectively. Clinical success was achieved in 113 (94.2%) patients, with bleeding-related complications noted in 7 (5.8%) patients. Conclusions: Manual compression aided by the Axiostat® hemostatic dressing is effective and safe in achieving hemostasis of the femoral arterial access site in patients undergoing endovascular treatment with a 4–8 Fr introducer sheath.

Overview

CoChat Summary

TL;DR

In this two-center retrospective series of 120 patients, manual compression aided by the Axiostat® hemostatic dressing after femoral arterial access with 4–8 Fr sheaths achieved primary technical success in 91.7% and clinical success in 94.2%, with bleeding-related vascular access site complications in 5.8%. The authors conclude the approach is effective and safe but call for larger randomized controlled trials because of the lack of a control group.

Key findings

  • Primary technical success was achieved in 110/120 patients (91.7%); secondary technical success was 100%. Mean time-to-hemostasis was 8.9 (±3.9) minutes and mean time-to-ambulation was 462 (±199) minutes.
  • Clinical success was achieved in 113/120 patients (94.2%); bleeding-related VASCs occurred in 7 patients (5.8%). The overall VASC rate was 8.3%, comprising 2 hematomas (1.7%), 5 pseudoaneurysms (4.1%), and 3 dissections (2.5%). No major bleeding events occurred; only CIRSE grade 2 or 3 events occurred, and no SVS major (grade 3) VASCs were noted. One pseudoaneurysm required US-guided percutaneous thrombin injection.
  • In subgroup comparison, primary technical success was significantly higher with 4–6 Fr sheaths than with 7–8 Fr sheaths (97.8% vs. 71.4%; p < 0.001), while intraoperative thrombolytic agent use was significantly higher in the 7–8 Fr group (25% vs. 1.1%; p < 0.001). No statistically significant differences were observed between groups for VASCs or bleeding-related VASCs.
  • Simple logistic regression identified coagulopathy (p = 0.036) and systolic pressure (p = 0.007) as significant single predictors of bleeding-related VASCs; multiple logistic regression found coagulopathy as the exception (p = 0.029), with the paper noting an average increase of 4.55 in the log odds of bleeding-related VASC occurrence for the coagulopathy group.

Methods

  • Two-center retrospective analysis of 120 consecutive patients who underwent manual compression closure of the femoral arterial access site aided by the Axiostat® hemostatic dressing from July 2022 to February 2023, after endovascular treatment with introducer sheaths ranging from 4 Fr to 8 Fr.
  • Protocol: Axiostat® was applied on the skin access site instead of cotton gauze; manual compression was performed for 7 minutes for 4–6 Fr sheaths and 10 minutes for 7–8 Fr sheaths, with continuation if needed. A pressure dressing was maintained for 6 hours (4–6 Fr) or 12 hours (7–8 Fr); color-coded duplex sonography was performed before discharge, and telephone follow-up occurred at 30 days.
  • Outcomes included primary technical success, clinical success, secondary technical success, time-to-hemostasis, time-to-ambulation, and VASC rate. Analysis used the modified intention-to-treat population, SPSS and R/R Studio, descriptive statistics, subgroup comparisons, t-test/Mann–Whitney/chi-squared/Fisher exact tests, and simple and multiple logistic regression with p < 0.05 considered significant.

Limitations

  • The paper states the main limitations as lack of randomization, absence of a control group, and small population size; it also notes the preliminary nature of the experience, heterogeneity of treatments and introducer sheaths, difficulty interpreting periprocedural anticoagulant therapy as a possible confounder, retrospective design providing inferior evidence, and scarcity of literature for comparison.
  • Evident from the text: the single-arm design means no direct comparison with manual compression alone or vascular closure devices, and the 30-day telephone follow-up may not capture later access-site complications.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jpm13050812

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Preparation and application of the Axiostat® hemostatic dressing. The skin around the vascular access site and the operators’ gloves are cleaned; Axiostat® is then prepared with cotton gauze (A). The interventionist moves Axiostat toward the introducer sheath (B), removes it and performs manual compression by placing the Axiostat® hemostatic dressing between their hand and the vascular access site (C). Upon removal of the introducer sheath, a few drops of blood spontaneously flow out of the access site, thus imbibing Axiostat® with blood and triggering a charge-based adhesion between the positively charged chitosan and the negatively charged blood.
Figure 1 Preparation and application of the Axiostat® hemostatic dressing. The skin around the vascular access site and the operators’ gloves are cleaned; Axiostat® is then prepared with cotton gauze (A). The interventionist moves Axiostat toward the introducer sheath (B), removes it and performs manual compression by placing the Axiostat® hemostatic dressing between their hand and the vascular access site (C). Upon removal of the introducer sheath, a few drops of blood spontaneously flow out of the access site, thus imbibing Axiostat® with blood and triggering a charge-based adhesion between the positively charged chitosan and the negatively charged blood.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 20 Not checked · 53 Own results and interpretations

39 more claims

Create a free account to see all 73 claims and to verify the 55 references still open.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Cited by

See all 20

Metadata

Authors
Minici, R., Serra, R., Maglia, C., Guzzardi, G., Spinetta, M., Fontana, F., Venturini, M., & Laganà, D.
Affiliations
  • Azienda Ospedaliero-Universitaria "Renato Dulbecco" (IT)
  • Magna Graecia University (IT)
  • Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
  • University of Insubria (IT)
Corresponding author
Laganà, Domenico
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2023-05-11
Volume
13
Issue
5
Pages
812
ISSN
2075-4426 (ISSN-L)
OpenAlex
W4378515386
Cited by
20
References
62
Citations by year
2026: 6 · 2025: 6 · 2024: 3 · 2023: 5
FWCI
3.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IrInSubria (University of Insubria) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vascular Procedures and Complications
  • Health Sciences › Medicine › Hematology › Hemostasis and retained surgical items
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Central Venous Catheters and Hemodialysis
Keywords
hemostasis, endovascular intervention, vascular closure devices, introducer sheath, bleeding complications, time to ambulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.